Related Experiment Video

Updated: Aug 9, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

[Atrial natriuretic factor in patients with hypertension]

A V Bil'chenko, Iu M Vasil'ev

    Kardiologiia
    |March 1, 1991
    PubMed

    Insights

    Plasma atrial natriuretic factor levels are higher in advanced hypertension and influenced by left ventricular hypertrophy. Enalapril maleate significantly reduced these levels, suggesting an antagonistic relationship with aldosterone.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Nephrology

    Context:

    • Essential hypertension and borderline arterial hypertension present complex physiological challenges.
    • Atrial natriuretic factor (ANF) plays a crucial role in cardiovascular and fluid balance regulation.
    • Understanding ANF's role in hypertension is vital for developing effective treatments.

    Purpose:

    • To investigate plasma atrial natriuretic factor (ANF) concentrations in patients with essential and borderline hypertension.
    • To explore the relationship between ANF, hemodynamic changes, natriuresis, and left ventricular hypertrophy.
    • To assess the effect of enalapril maleate on plasma ANF levels.

    Summary:

    • Radioimmunoassay revealed elevated plasma ANF in Stage II hypertensive patients, linked to hemodynamic changes.
    • A weaker ANF-natriuresis correlation was observed in early essential hypertension.
    • Left ventricular hypertrophy significantly impacted plasma ANF levels.
    • An inverse correlation between ANF and plasma aldosterone suggests antagonistic roles in homeostasis.
    • Enalapril maleate treatment significantly reduced plasma ANF concentrations.

    Impact:

    • Findings elucidate the complex interplay of ANF in hypertensive states.
    • Highlights the influence of cardiac structure (left ventricular hypertrophy) on ANF levels.
    • Provides insights into the mechanism of action for antihypertensive drugs like enalapril maleate.
    • Suggests potential therapeutic targets for managing hypertension and fluid-electrolyte balance.

    More Related Videos

    Isolation of Atrial Myocytes from Adult Mice08:34

    Isolation of Atrial Myocytes from Adult Mice

    Published on: July 25, 2019

    Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

    Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

    Published on: August 2, 2024

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Hormonal Regulation of Blood Pressure01:17

    Hormonal Regulation of Blood Pressure

    Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
    Epinephrine and Norepinephrine
    The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...